News Conference News AHA 2016 Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding Shelley Wood November 21, 2016
News Daily News Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation Michael O'Riordan October 07, 2016
News Daily News Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns Shelley Wood September 13, 2016
News Conference News ESC 2016 NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry Michael O'Riordan August 28, 2016
News Daily News FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors Michael O'Riordan August 18, 2016
News Daily News New PFO Guidelines: No Routine Offer of Closure for Cryptogenic Stroke, Says American Academy of Neurology Shelley Wood July 27, 2016
News Daily News Un Estudio del Mundo Real Confirma los Efectos de Apixaban y Rivaroxaban en el Manejo de la FA Todd Neale April 21, 2016
News Daily News Real-World Study Largely Confirms Effects of Apixaban, Rivaroxaban for A-fib Todd Neale April 21, 2016
News Conference News ACC 2016 Comparing the Novel Oral Anticoagulants: Effectiveness Similar, but Apixaban May Come With Less Bleeding Todd Neale April 06, 2016
News Daily News US Cardiologists Are Underusing Oral Anticoagulation for A-fib Todd Neale March 21, 2016
News Daily News Los Cardiólogos de EE.UU. Infrautilizan la Anticoagulación Oral en el Manejo de la FA Todd Neale March 21, 2016
News Daily News Real-World Traumatic Intracranial Bleeding in Elderly, Warfarin-Treated Patients a Bigger Problem Than Seen in Trials Todd Neale March 09, 2016
News Conference News ISC 2016 To Anticoagulate or Not? Debating Secondary Stroke Prevention in an A-fib Patient With Microbleeds Michael O'Riordan February 23, 2016
News Daily News In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients Todd Neale January 25, 2016
News Daily News Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction L.A. McKeown December 14, 2015
Presentation Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure Presenter: Vivek Y. Reddy December 13, 2015
News Industry News CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) September 25, 2015
News Daily News Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding Yael L. Maxwell July 10, 2015